Fundraising Fox
/Companies
Sign in

Gamgee

YC S26

Tampa, US · Founded 2026 · 2 employees · 4 known investors

Find your way into Gamgee

Sign up to see every warm intro you have to Gamgee

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Gamgee team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

GAMGEE develops personalised mRNA cancer vaccines for dogs, created from the animal's own tumour tissue to help its immune system fight the cancer. The company manages the full process end to end—from diagnosis and tissue sampling with the pet owner's vet, to genomic analysis and treatment delivery via veterinary oncologists—and is currently running clinical trials in Australia while accepting applications globally.

Also known as Gamgee Technologies

AI & Machine LearningBiotechDeep TechHealthtechGenomicsOncologyAIUnited States of AmericaAmerica / CanadaFully Remote

Founders & leadership· Y Combinator alumni (S26)

Gamgee was founded in 2026 by Paul Conyngham and Robert Quinn.

PCPaul Conyngham
Paul ConynghamCEOPaul Conyngham co-founded Core Intelligence, which developed applied AI systems for startups and enterprise, and has worked on machine learning, data science, and electrical and computer systems engineering. He is founder of Gamgee Technologies, which develops personalized mRNA cancer vaccines.
RQ
Robert QuinnCo-founder

Board

VK
Vinod KhoslaBoard director

Investors · 4

WSSlisted by WSS

How we know: Y Combinator's founder network · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Blast.Clubreported$5.5M

How we know: Y Combinator's founder network · Not right? Tell us

Maiora Rebel Venturesreported

How we know: Y Combinator's founder network · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$4M disclosed across 1 round · 2014

▶$4MraisedNov 2014 · 3 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert QuinnExecutive Officer, Director, Promoter
  • Vinod KhoslaDirector
Offering amount
$4M
Amount sold
$4M
First sale
Nov 2014
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Helix NanotechnologiesHelix Nanotechnologies develops mRNA-based therapeutics for disease treatment and environmental applications, currently advancing a COVID-19 vaccine candidate for immunocompromised patients and testing interventions targeting climate challenges.
Cisterna BiologicsCisterna Biologics develops yeast-engineered mRNA manufacturing technology that can be selectively purified to drive protein expression in human cells. The company targets cost-effective, scalable, and non-immunogenic mRNA production for therapeutic applications.
Cambridge Cancer GenomicsCCG.ai develops software that uses clinical and genomic data to help oncologists select appropriate cancer treatments for individual patients, with a focus on identifying predictive biomarkers linked to treatment response.
Guardian BioGuardian Bio develops dendritic cell therapy for solid tumors by generating cDC1 cells from patient stem cells to restore immune function in cancer treatment. The company targets late-stage cancer patients who have dysfunctional antigen presentation.
Kopra BioKopra Bio develops cancer immunotherapy technology that converts cancer cells into biofactories to produce their own destruction. The company operates in the biotech and cancer treatment space.

Companies working in the same space as Gamgee.

Legal entities · 1

corporate structure
Gamgee Technologies

Frequently asked questions

What does Gamgee do?
GAMGEE develops personalised mRNA cancer vaccines for dogs, created from the animal's own tumour tissue to help its immune system fight the cancer. The company manages the full process end to end—from diagnosis and tissue sampling with the pet owner's vet, to genomic analysis and treatment delivery via veterinary oncologists—and is currently running clinical trials in Australia while accepting applications globally.
Who founded Gamgee?
Gamgee was founded by Paul Conyngham, Robert Quinn in 2026.
Who are Gamgee's investors?
Gamgee's investors include WSS, Y Combinator, Blast.Club, Maiora Rebel Ventures.
How much funding has Gamgee raised?
Gamgee has disclosed $4M raised across 1 round.
Where is Gamgee headquartered?
Gamgee is headquartered in Tampa, US.